Wild Damian, Béhé Martin, Wicki Andreas, Storch Daniel, Waser Beatrice, Gotthardt Martin, Keil Boris, Christofori Gerhard, Reubi Jean Claude, Mäcke Helmut R
Clinic and Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
J Nucl Med. 2006 Dec;47(12):2025-33.
UNLABELLED: High levels of glucagon-like peptide-1 (GLP-1) receptor expression in human insulinomas and gastrinomas provide an attractive target for imaging, therapy, and intraoperative tumor localization, using receptor-avid radioligands. The goal of this study was to establish a tumor model for GLP-1 receptor targeting and to use a newly designed exendin-4-DTPA (DTPA is diethylenetriaminepentaacetic acid) conjugate for GLP-1 receptor targeting. METHODS: Exendin-4 was modified C-terminally with Lys(40)-NH(2), whereby the lysine side chain was conjugated with Ahx-DTPA (Ahx is aminohexanoic acid). The GLP-1 receptor affinity (50% inhibitory concentration [IC(50)] value) of [Lys(40)(Ahx-DTPA)NH(2)]exendin-4 as well as the GLP-1 receptor density in tumors and different organs of Rip1Tag2 mice were determined. Rip1Tag2 mice are transgenic mice that develop insulinomas in a well-defined multistage tumorigenesis pathway. This animal model was used for biodistribution studies, pinhole SPECT/MRI, and SPECT/CT. Peptide stability, internalization, and efflux studies were performed in cultured beta-tumor cells established from tumors of Rip1Tag2 mice. RESULTS: The GLP-1 receptor affinity of [Lys(40)(Ahx-DTPA)NH(2)]exendin-4 was found to be 2.1 +/- 1.1 nmol/L (mean +/- SEM). Because the GLP-1 receptor density in tumors of Rip1Tag2 mice was very high, a remarkably high tumor uptake of 287 +/- 62 %IA/g (% injected activity per gram tissue) was found 4 h after injection. This resulted in excellent tumor visualization by pinhole SPECT/MRI and SPECT/CT. In accordance with in vitro data, [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4 uptake in Rip1Tag2 mice was also found in nonneoplastic tissues such as pancreas and lung. However, lung and pancreas uptake was distinctly lower compared with that of tumors, resulting in a tumor-to-pancreas ratio of 13.6 and in a tumor-to-lung ratio of 4.4 at 4 h after injection. Furthermore, in vitro studies in cultured beta-tumor cells demonstrated a specific internalization of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4, whereas peptide stability studies indicated a high metabolic stability of the radiopeptide in beta-tumor cells and human blood serum. CONCLUSION: The high density of GLP-1 receptors in insulinomas as well as the high specific uptake of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4 in the tumor of Rip1Tag2 mice indicate that targeting of GLP-1 receptors in insulinomas may become a useful imaging method to localize insulinomas in patients, either preoperatively or intraoperatively. In addition, Rip1Tag2 transgenic mice represent a suitable animal tumor model for GLP-1 receptor targeting.
未标记:人胰岛素瘤和胃泌素瘤中高水平的胰高血糖素样肽-1(GLP-1)受体表达为使用受体亲和放射性配体进行成像、治疗及术中肿瘤定位提供了一个有吸引力的靶点。本研究的目的是建立一个用于GLP-1受体靶向的肿瘤模型,并使用一种新设计的艾塞那肽-4-二乙三胺五乙酸(DTPA)偶联物进行GLP-1受体靶向。 方法:艾塞那肽-4在C末端用赖氨酸(40)-NH₂修饰,其中赖氨酸侧链与氨基己酸-DTPA(Ahx是氨基己酸)偶联。测定了[赖氨酸(40)(氨基己酸-DTPA)NH₂]艾塞那肽-4的GLP-1受体亲和力(50%抑制浓度[IC₅₀]值)以及Rip1Tag2小鼠肿瘤和不同器官中的GLP-1受体密度。Rip1Tag2小鼠是在明确的多阶段肿瘤发生途径中发生胰岛素瘤的转基因小鼠。该动物模型用于生物分布研究、针孔单光子发射计算机断层扫描/磁共振成像(SPECT/MRI)以及SPECT/计算机断层扫描(CT)。在从Rip1Tag2小鼠肿瘤建立的培养β肿瘤细胞中进行了肽稳定性、内化和外排研究。 结果:发现[赖氨酸(40)(氨基己酸-DTPA)NH₂]艾塞那肽-4的GLP-1受体亲和力为2.1±1.1 nmol/L(平均值±标准误)。由于Rip1Tag2小鼠肿瘤中的GLP-1受体密度非常高,注射后4小时发现肿瘤摄取率显著高,为287±62%IA/g(每克组织注射活性百分比)。这通过针孔SPECT/MRI和SPECT/CT实现了出色的肿瘤可视化。与体外数据一致,在Rip1Tag2小鼠中,[赖氨酸(40)(氨基己酸-(铟-111)DTPA)NH₂]艾塞那肽-4在胰腺和肺等非肿瘤组织中也有摄取。然而,与肿瘤相比,肺和胰腺的摄取明显较低,注射后4小时肿瘤与胰腺的比值为13.6,肿瘤与肺的比值为4.4。此外,在培养的β肿瘤细胞中的体外研究表明[赖氨酸(40)(氨基己酸-(铟-111)DTPA)NH₂]艾塞那肽-4有特异性内化,而肽稳定性研究表明放射性肽在β肿瘤细胞和人血清中具有高代谢稳定性。 结论:胰岛素瘤中GLP-1受体的高密度以及[赖氨酸(40)(氨基己酸-(铟-111)DTPA)NH₂]艾塞那肽-4在Rip1Tag2小鼠肿瘤中的高特异性摄取表明,靶向胰岛素瘤中的GLP-1受体可能成为一种有用的成像方法,用于在术前或术中定位患者的胰岛素瘤。此外,Rip1Tag2转基因小鼠代表了一种适用于GLP-1受体靶向的动物肿瘤模型。
Eur J Nucl Med Mol Imaging. 2010-1-29
Lancet Diabetes Endocrinol. 2013-7-25
Eur J Nucl Med Mol Imaging. 2002-5
Diagn Interv Imaging. 2025-5-21
Front Mol Biosci. 2023-9-15
EJNMMI Radiopharm Chem. 2023-9-4
Curr Oncol Rep. 2021-11-4